XML 94 R11.htm IDEA: XBRL DOCUMENT
v3.20.1

Acquisitions | 9 Months Ended
--- | ---
Mar. 31, 2020
Business Combinations [Abstract] |
Acquisitions | Acquisitions Bemis Company, Inc. On June 11, 2019, the Company completed the acquisition of 100% of the outstanding shares of Bemis Company, Inc. ("Bemis"), a global manufacturer of flexible packaging products based in the United States. Pursuant to the Transaction Agreement, dated as of August 6, 2018, each outstanding share of Bemis common stock that was issued and outstanding upon completion of the transaction was converted into the right to receive 5.1 ordinary shares of the Company traded on the New York Stock Exchange ("NYSE"). The following table summarizes the fair value of consideration exchanged:
Bemis shares outstanding at June 11, 2019 (in millions) |  | 91.7 |
Share exchange ratio |  | 5.1 |
Price per share (based on Amcor’s closing share price on June 11, 2019) |  | $ | 11.18 |
Total equity consideration ($ in millions) |  | $ | 5,229.6 |
The acquisition of Bemis positions the Company as a global leader in consumer packaging with a comprehensive global footprint in flexible packaging and greater scale in key regions of North America, Latin America, Asia Pacific and Europe, along with industry-leading research and development capabilities. The acquisition of Bemis was accounted for as a business combination in accordance with ASC 805, "Business Combinations," which required allocation of the purchase price to the estimated fair values of assets acquired and liabilities assumed in the transaction. The Company has made measurement period adjustments at March 31, 2020 resulting in a $117.2 million increase to goodwill, which includes a $170.0 million decrease to property, plant and equipment, a $98.8 million decrease to finite lived intangible assets, a $163.7 million decrease to deferred tax liabilities, along with other adjustments to assets held for sale and working capital. The Company estimated the preliminary fair value of acquired assets and liabilities as of the acquisition date based on information currently available and has adjusted those estimates primarily upon further evaluation of property and equipment acquired, and related adjustment to finite lived intangibles acquired and deferred taxes. The allocation of fair value for the assets and liabilities acquired remains preliminary given the number of global locations acquired and may continue to be adjusted up to one year after the acquisition. Accordingly, final determination of the fair values may result in further adjustments to the values presented in the following table.
($ in millions) |  |
Cash and cash equivalents |  | $ | 3.3 |
Trade receivables |  | 433.8 |
Inventories |  | 673.5 |
Prepaid expenses and other current assets |  | 82.0 |
Assets held for sale |  | 464.2 |
Property, plant and equipment |  | 1,220.7 |
Deferred tax assets |  | 35.5 |
Other intangible assets |  | 1,931.4 |
Other non-current assets |  | 47.0 |
Total identifiable assets acquired |  | 4,891.4 |
Current portion of long-term debt |  | 1.7 |
Short-term debt |  | 8.6 |
Trade payables |  | 288.2 |
Accrued employee costs |  | 165.6 |
Other current liabilities |  | 304.4 |
Liabilities held for sale |  | 21.9 |
Long-term debt, less current portion |  | 1,365.3 |
Deferred tax liabilities |  | 618.9 |
Employee benefit obligation |  | 62.6 |
Other non-current liabilities |  | 79.5 |
Total liabilities assumed |  | 2,916.7 |
Net identifiable assets acquired |  | 1,974.7 |
Goodwill |  | 3,254.9 |
Net assets acquired |  | $ | 5,229.6 |
The following table details the preliminary identifiable intangible assets acquired from Bemis, their fair values and estimated useful lives:
|  | Fair Value |  | Weighted-average Estimated Useful Life
|  | ($ in millions) |  | (Years)
Customer relationships |  | $ | 1,650.0 |  |  | 15
Technology |  | 110.0 |  |  | 7
Other |  | 171.4 |  |  | 7
Total other intangible assets |  | $ | 1,931.4 |  |  |
The purchase price allocation is preliminary in nature and subject to adjustments, which could be material. Any necessary adjustments will be finalized within one year from the date of acquisition. The preliminary allocation of the purchase price as of March 31, 2020 has resulted in $3,254.9 million of goodwill for the Flexibles segment, which is not tax deductible. The goodwill on acquisition represents the future economic benefit expected to arise from other intangible assets acquired that do not qualify for separate recognition, including assembled workforce and non-contractual relationships, as well as expected future synergies. As the Company finalizes the valuation of assets acquired and liabilities assumed, it will determine to which reporting units within the Company's segments any changes in goodwill should be recorded. The fair value measurement of tangible and intangible assets and liabilities was based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value measurement hierarchy. Level 3 fair market values were determined using a variety of information, including estimated future cash flows, appraisals and market comparables. Closing of the Bemis acquisition was conditional upon the receipt of regulatory approvals, approval by both Amcor and Bemis shareholders, and satisfaction of other customary conditions. In order to satisfy certain regulatory approvals, the Company was required to divest three of Bemis' medical packaging facilities located in the United Kingdom and Ireland ("EC Remedy") and three Amcor medical packaging facilities in the United States ("U.S. Remedy"). The U.S. Remedy was completed during the fourth quarter of fiscal 2019 and the Company received $214.2 million resulting in a gain of $159.1 million. The EC Remedy was completed during the first quarter of fiscal 2020 and the Company received $397.1 million and recorded a loss on the sale of $8.8 million which is the result of the reclassification of accumulated foreign currency translation amounts from accumulated other comprehensive income to earnings from discontinued operations upon sale of the EC Remedy.

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration